Sang­amo splits the R from the D in a re­or­ga­ni­za­tion — and bids chief farewell

A lot of big or grow­ing bio­phar­ma com­pa­nies ask them­selves whether re­search and de­vel­op­ment should be split in­to two sep­a­rate groups or head­ed up by a sin­gle top R&D chief. Sang­amo $SG­MO has been go­ing through that ex­er­cise, and came up in fa­vor of a split.

And their se­nior re­search ex­ec isn’t go­ing to be in charge of ei­ther.

Adri­an Woolf­son, a Pfiz­er vet who had been ex­ec­u­tive vice pres­i­dent of R&D at Sang­amo for the past 18 months as the biotech sought to catch up with Bio­Marin’s he­mo­phil­ia A gene ther­a­py, has ex­it­ed the com­pa­ny, ac­cord­ing to a state­ment from Sang­amo CEO Sandy Macrae. And Ja­son Fontenot, SVP of cell ther­a­py, will go for­ward as in­ter­im head of re­search while the com­pa­ny looks for a new head of de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.